Bi-functional shRNA for Selective KRAS Mutation Knockdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting KRAS mutations, such as small molecules and antibodies, are ineffective in patients with KRAS mutations, necessitating a need for compositions and treatments that selectively reduce mutant KRAS expression without affecting wild-type functionality.
Innovation Solution
Development of bi-functional short-hairpin RNA (bi-shRNA) that selectively targets mutant KRAS sequences, utilizing guide strands fully complementary to the target site with passenger strands containing mismatches, activating both cleavage-dependent and cleavage-independent RNA-induced silencing complexes for reduced expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies (small molecules or antibodies) are used to target KRAS mutations, then treatment is attempted, but they are ineffective in patients with KRAS mutations
Solution Approach 1:
The guide strand is designed with a mismatched base at position 2, 3, or 4 that specifically recognizes the mutant KRAS sequence, creating local differentiation between mutant and wild-type targeting. This localized mismatch provides mutation-selective binding affinity while maintaining overall guide strand functionality, enabling reliable therapeutic effect specifically in mutant-bearing cells
Solution Approach 2:
The patent modifies the binding parameters of the guide strand by introducing a single nucleotide mismatch at critical positions (2, 3, or 4), which changes the thermodynamic and kinetic properties of RNA-RNA hybridization. This parameter change creates differential binding affinity: strong binding to mutant sequences with the mismatch, and weak or no binding to wild-type sequences, thereby achieving mutation selectivity and therapeutic efficacy
2Productivity
If guide strands are made fully complementary to mutant target site, then knockdown efficiency is improved, but specificity against wild-type KRAS must be maintained
Solution Approach 1:
A single nucleotide mismatch is introduced at positions 2, 3, or 4 of the guide strand, creating a localized region of imperfection in an otherwise fully complementary sequence. This local quality change disproportionately affects binding to wild-type versus mutant sequences, enabling high knockdown efficiency for mutants while maintaining specificity through the localized discrimination mechanism
Solution Approach 2:
The guide strand is designed with asymmetric complementarity: fully complementary to the mutant sequence except for one intentional mismatch, creating an asymmetric binding profile. This asymmetry ensures that the guide strand binds strongly to mutant mRNA (achieving high knockdown efficiency) but binds weakly or not at all to wild-type mRNA (achieving high discrimination accuracy)
3Adaptability or versatility
If passenger strands contain mismatches to enable cleavage-independent silencing, then RNAi pathway activation is improved, but structural perfection is reduced
Solution Approach 1:
Mismatches are strategically introduced only in the passenger strand at specific positions, creating local imperfections that do not compromise the overall stem-loop structure. These localized mismatches in the passenger strand specifically promote loading into cleavage-independent RISC pathways while the guide strand maintains full complementarity to ensure target recognition and structural stability
Solution Approach 2:
The shRNA molecule is functionally segmented into distinct roles: the guide strand maintains structural integrity and target recognition capability, while the passenger strand contains the mismatches that enable versatile RNAi pathway activation. This segmentation allows the two strands to have different compositional requirements, with the passenger strand tolerating mismatches for pathway diversification while the guide strand remains structurally perfect for stable target binding
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bi-shRNA achieves selective and efficient knockdown of mutant KRAS gene products, potentially reducing tumor proliferation and invasiveness, with minimal impact on wild-type KRAS expression, and is delivered via compacted DNA nanoparticles encapsulated in liposomes for therapeutic efficacy.
Implementation Method 1
one or more short hairpin RNA (shRNA) that selectively inhibits expression of a mutated K-ras gene product via RNA interference
Data Source
Figure 1~2
Figure 3A~3C
Figure 4~5
AI summary
The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of a K-ras gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA molecule is located within the K-ras gene and wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of K-ras.